New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
09:23 EDTTEVA, PFE, AMGN, JNJTeva acquisition a positive for Amgen, says Piper Jaffray
Piper Jaffray views Teva's (TEVA) acquisition of Labrys as a positive for Amgen (AMGN) since a potential competitor has stayed out of the hands of "formidable marketing wheelhouses" like Johnson & Johnson (JNJ) or Pfizer (PFE). Piper believes Amgen is in the lead for antibodies targeting CGRP receptor and Labrys is in the lead for antibodies targeting the CGRP ligand. It reiterates an Overweight rating on shares of Amgen.
News For AMGN;TEVA;JNJ;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 7, 2014
14:18 EDTAMGNAmgen, Onyx announce detailed results from Phase 3 ASPIRE study of Kyprolis
Subscribe for More Information
14:10 EDTAMGNAmerican Society of Hematology to hold a meeting
Subscribe for More Information
December 5, 2014
10:22 EDTPFEBristol-Myers call activity attributed to takeover speculation
Subscribe for More Information
10:05 EDTPFEBristol-Myers jumps 2% amid talk of potential Pfizer bid
Shares of Bristol-Myers (BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer (PFE). The stock is up $1.26 to $60.15. Bristol's market capitalization stands around $99B, less than twice that of Pfizer's $200B. A Jefferies analyst last week called Mylan (MYL) the most likely takeover target for Pfizer. Pfizer is "highly motivated" to buy a foreign company using its overseas cash and Mylan looks like the most likely target, Jefferies analyst Jeffrey Holford wrote.
09:56 EDTPFERumor: Bristol-Myers strength attributed to takeover speculation
Subscribe for More Information
07:54 EDTTEVALannett names Michael Bogda as president, effective December 1
Subscribe for More Information
December 4, 2014
13:26 EDTAMGNAmgen to host investor meeting
Investor meeting to be held in conjunction with the American Society of Hematology's 56t Annual Meeting in San Francisco on December 8 at 3 pm. Webcast Link
11:23 EDTJNJAppeals court reverses patent ruling in favor of J&J unit over Covidien
Ethicon Endo-Surgery, a Johnson & Johnson (JNJ) company, appealed a district court judgment regarding certain asserted patent claims of Tyco Healthcare. The appeals court affirmed-in-part, reversed-in-part, and vacated-in-part the prior judgment, because the lower court’s 102(g) findings were correct, but its 103 determination was improper, "including its decision to exclude the 102(g) prior art from the obviousness analysis," the court stated. In 2007, Tyco Healthcare changed its name to Covidien (COV). Reference Link
10:32 EDTTEVATeva receives positive outcomes in Europe for three-times-a-week COPAXONE
Teva Pharmaceutical Industries announced that it has received a positive outcome in the decentralized procedure for its new, three-times-a-week COPAXONE 40 mg/ml formulation for the treatment of adults with relapsing forms of multiple sclerosis RMS. The outcome follows a Positive Assessment Report from the United Kingdom, the Reference Member State’s Medicines and Healthcare Products Regulatory Agency, and all Concerned Member States in Europe who were involved in the procedure. Granting of national authorizations will happen in the near future. The three-times-a-week COPAXONE 40 mg/ml formulation will allow for an improved, less-frequent, subcutaneous dosing regimen for adults with RMS. The new formulation reduces the total number of injections by almost 60%, while maintaining the known benefits of once daily COPAXONE 20 mg/ml. “We welcome the opportunity to make COPAXONE 40 mg/ml available to patients with RMS in Europe,” said Rob Koremans, MD, President and CEO of Global Specialty Medicines at Teva. “Three-times-a-week COPAXONE 40 mg/ml will be available in Europe as early as the first quarter of 2015 with expected launches in Germany, Netherlands and Denmark. Launches in other EU countries are expected throughout 2015.”
09:01 EDTJNJVA negotiated $594 per dose price for Gilead HCV treatment
A Veterans Health Administration official told a Senate committee yesterday that Veterans' Affairs has "moved rapidly to deploy new, more effective, less toxic HCV treatments and has been able to negotiate significant discounts for these newer therapies." The agency negotiated a price of $594 per dose for Gilead's (GILD) Hepatitis C virus drug Sofosbuvir, below the commercial price of $1,000 per dose, VHA Chief Consultant for Pharmacy Benefits Management Michael Valentino told the Senate's Committee on Veterans' Affairs. The agency also received a $413 per dose price for Johnson & Johnson's (JNJ) Simeprevir, below the commerical price of $790. The VA has approximately 174,000 veterans in care with HCV, making it the largest single HCV provider in the U.S., Valentino pointed out. He added, "Like the rest of the country, VA has treated only a portion of Veterans for HCV because treatment and cures have been difficult to achieve due to low efficacy and high toxicity of standard drug therapies." Reference Link
08:45 EDTPFEAbbVie price target raised to $80 from $72 at Jefferies
Jefferies raised its price target for AbbVie shares to $80 while calling the company one of its top five global pharma picks for 2015. The firm's top U.S. pick is Pfizer (PFE) and its top Europe pick is Novartis (NVS). Bayer (BAYRY) and AstraZeneca (AZN) round out the top five. Jefferies thinks AbbVie's "strong momentum" will continue into the first half of 2015 and keeps a Buy rating on the name.
05:30 EDTTEVACTI BioPharma receives $15M payment from Teva for TRISENOX
Subscribe for More Information
December 3, 2014
17:12 EDTPFEPfizer reports positive results from PROFILE 1014 study
Subscribe for More Information
16:42 EDTPFEDiplomat chosen as limited-distribution pharmacy partner by Pfizer
Subscribe for More Information
15:51 EDTAMGNAmgen confirms FDA approval for BLINCYTO
Amgen announced that the FDA has granted approval of BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials. With this approval, BLINCYTO becomes the first FDA-approved bispecific CD19-directed CD3 T-cell engager antibody construct product, and the first single-agent immunotherapy to be approved for the treatment of patients with Ph- relapsed or refractory B-cell precursor ALL, the company said. BLINCYTO has a BOXED WARNING in its product label regarding Cytokine Release Syndrome and Neurological Toxicities.
13:13 EDTAMGNAmgen drug for rare form of ALL approved by FDA
The FDA said it approved Blincyto to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, an uncommon form of ALL. Blincyto carries a boxed warning alerting patients and health care professionals that some clinical trial participants had problems with low blood pressure and difficulty breathing at the start of the first treatment, or other side effects in the nervous system. The FDA approved Blincyto with a Risk Evaluation and Mitigation Strategy, which consists of a communication plan to inform health care providers about the serious risks and the potential for preparation and administration errors. Blincyto is marketed by Amgen.
10:08 EDTJNJJ&J hires Goldman to explore sale of Splenda brand, Reuters says
Subscribe for More Information
09:45 EDTJNJJohnson & Johnson hires bank to explore sale of Splenda brand, Reuters says
09:35 EDTJNJActive equity options trading
Subscribe for More Information
07:16 EDTPFEFood & Drug Law Institute to hold a conference
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use